Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Case Based Panel Discussion 2019 - Progression Post ALK Inhibitor - Role For Combination Therapies?
Is there is a role for combination therapies like chemotherapy/Avastin and immunotherapy?
Author
Howard (Jack) West, MD
Image
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.

Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/Avastin and immunotherapy.

 

 

To join the conversation, visit https://cancergrace.org/forum

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora